(Rac)-Benpyrine|cas:1333714-43-4|西域试剂

(Rac)-Benpyrine,99.30%

产品编号：Bellancom-133807A| CAS NO：1333714-43-4| 分子式：C₁₆H₁₆N₆O| 分子量：308.34

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-133807A	￥1800.00	杭州北京（现货）
Bellancom-133807A	￥2800.00	杭州北京（现货）
Bellancom-133807A	￥8000.00	杭州北京（现货）
Bellancom-133807A	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

(Rac)-Benpyrine

产品介绍

(Rac)-Benpyrine，Benpyrine 的外消旋体，是一种有效的具有口服活性的 TNF-α 抑制剂。(Rac)-Benpyrine 可用于 TNF-α 介导的炎症和自身免疫性疾病的研究。

生物活性

(Rac)-Benpyrine, a racemate of Benpyrine, is a potent and orally active TNF-α inhibitor. (Rac)-Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research.

体外研究

(Rac)-Benpyrine (Compound 001; 5-10 μM; 24 hours) treatment inhibits the expression level of TNF-α downstream pathway protein NF-κB in the nucleus in RAW264.7 macrophages.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

(Rac)-Benpyrine (Compound 001; 25-50 mg/kg; oral gavage; daily; for 3 weeks; Kunming mice) treatment obviously reduces the inflammatory cytokines IFN-γ, IL-1β and IL-6 in the blood serum, and the anti-inflammatory factor IL-10 is obviously increased, the foot swelling degree of the arthritis part is also obviously slowed down, and the weight index increase caused by the arthritis also has no obvious reduction.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Kunming mice (7-8 weeks) treated with bovine type II collagen and a CFA complete adjuvant
Dosage:	25 mg/kg, 50 mg/kg
Administration:	Oral gavage; daily; for 3 weeks
Result:	The inflammatory cytokines IFN-γ, IL-1β and IL-6 in the blood serum were obviously reduced, and the anti-inflammatory factor IL-10 was obviously increased.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Kunming mice (7-8 weeks) treated with bovine type II collagen and a CFA complete adjuvant
Dosage:	25 mg/kg, 50 mg/kg
Administration:	Oral gavage; daily; for 3 weeks
Result:	The inflammatory cytokines IFN-γ, IL-1β and IL-6 in the blood serum were obviously reduced, and the anti-inflammatory factor IL-10 was obviously increased.

性状

Solid

溶解性数据

In Vitro:

DMSO : 12.5 mg/mL (40.54 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2432 mL	16.2159 mL	32.4317 mL
5 mM	0.6486 mL	3.2432 mL	6.4863 mL
10 mM	0.3243 mL	1.6216 mL	3.2432 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.25 mg/mL (4.05 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (4.05 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (4.05 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (4.05 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (4.05 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (4.05 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。